Pure Global
NCT06297785

Online, Gut-directed Hypnotherapy for Patients With Irritable Bowel Syndrome (IBS)

Sahlgrenska University Hospital, Sweden·ClinicalTrials.gov·behavioralRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
IBS - Irritable Bowel Syndrome
Drug/Device/Intervention
Gut-directed hypnotherapy
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Sahlgrenska University Hospital, Sweden
Location
Gothenburg,Gothenburg, Sweden
Timeline & enrollment
Phase
N/A
Start date
Oct 17, 2022
End date
Apr 01, 2027
Enrollment
50 participants
Primary outcome

Change in gastrointestinal symptom severity measured by the IBS Severity Scoring System questionnaire (IBS-SSS)

Summary

Adult IBS patients with symptoms refractory to standard medical treatment will receive online
 nurse-administered, gut-directed hypnotherapy in groups. The primary outcome measure was
 change in gastro-intestinal symptom severity.

ICD-10 classifications
Irritable bowel syndrome with predominant constipation [IBS-C]Irritable bowel syndromeIrritable bowel syndrome with predominant diarrhoea [IBS-D]Irritable bowel syndrome with mixed bowel habits [IBS-M]Other and unspecified irritable bowel syndrome
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06297785
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06297785 through Pure Global AI's free database. This phase not specified trial is sponsored by Sahlgrenska University Hospital, Sweden and is currently Recruiting. The study focuses on IBS - Irritable Bowel Syndrome. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.